Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions

Journal of Virology

Volumn 77, Issue 10, 2003, Pages 5810-5820

  Gaddis, Nathan C ^a   Chertova, Elena ^b   Sheehy, Ann M ^a,c   Henderson, Louis E ^b   Malim, Michael H ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SAIC FREDERICK INC   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFER RNA; VIF PROTEIN;

ARTICLE; ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION; T LYMPHOCYTE; VIRION;

CELL LINE; GENE PRODUCTS, VIF; HIV INFECTIONS; HIV-1; HUMANS; RNA, TRANSFER, LYS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VIRION; VIRUS REPLICATION;

EID: 0037630009     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.10.5810-5820.2003     Document Type: Article

References (69)

1. Akari, H., T. Uchiyama, T. Fukumori, S. Iida, H. Koyama, and A. Adachi. 1999. Pseudotyping human immunodeficiency virus type 1 by vesicular stomatitis virus G protein does not reduce the cell-dependent requirement of Vif for optimal infectivity: functional difference between Vif and Nef. J. Gen. Virol. 80:2945-2949.
2. Baraz, L., A. Friedler, I. Blumenzweig, O. Nussinuv, N. Chen, M. Steinitz, C. Gilon, and M. Kotler. 1998. Human immunodeficiency type 1 Vif-derived peptides inhibit the viral protease and arrest viral production. FEBS Lett. 441:419-426.
3. Beerens, N., B. Klaver, and B. Berkhout. 2000. A structured RNA motif is involved in correct placement of the tRNA(3)(Lys) primer onto the human immunodeficiency virus genome. J. Virol. 74:2227-2238.
4. Berkhout, B., A. T. Das, and N. Beerens. 2000. HIV-1 RNA editing, hypermutation, and error-prone reverse transcription. Science 292:7.
5. Blumenzweig, I., L. Baraz, A. Friedler, H. Danielson, C. Gilon, M. Steinitz, and M. Kotler. 2002. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases. Biochem. Biophys. Res. Commun. 292:832-840.
6. - mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J. Virol. 69:2058-2067.
7. Bourara, K., S. Litvak, and A. Araya. 2000. Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing. Science 289:1564-1566.
8. Gag precursor. J. Virol. 71:9358-9365.
9. - human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J. Virol. 71:2473-2477.
10. Bukrinskaya, A. G., A. Ghorpade, N. K. Heinzinger, T. E. Smithgall, R. E. Lewis, and M. Stevenson. 1996. Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc. Natl. Acad. Sci. USA 93:367-371.
11. Camaur, D., and D. Trono. 1996. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70:6106-6111.
12. Cartier, C., M. Deckert, C. Grangeasse, R. Trauger, F. Jensen, A. Bernard, A. Cozzone, C. Desgranges, and V. Boyer. 1997. Association of ERK2 mitogen-activated protein kinase with human immunodeficiency virus particles. J. Virol. 71:4832-4837.
13. Cartier, C., P. Sivard, C. Tranchat, D. Decimo, C. Desgranges, and V. Boyer. 1999. Identification of three major phosphorylation sites within HIV-1 capsid: role of phosphorylation during the early steps of infection. J. Biol. Chem. 274:19434-19440.
14. Chowdhury, I. H., W. Chao, M. J. Potash, P. Sova, H. E. Gendelman, and D. J. Volsky. 1996. vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J. Virol. 70:5336-5345.
15. - human immunodeficiency virus type 1 particle which are restricted for the preretrotranscription steps. J. Virol. 69:2068-2074.
16. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431-1437.
17. Dettenhofer, M., S. Cen, B. A. Carlson, L. Kleiman, and X.-F. Yu. 2000. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol. 74:8938-8945.
18. Dornadula, G., S. Yang, R. J. Pomerantz, and H. Zhang. 2000. Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J. Virol. 74:2594-2602.
19. Fan, L., and K. Peden. 1992. Cell-free transmission of Vif mutants of HIV-1. Virology 190:19-29.
20. Fisher, A. G., B. Ensoli, L. Ivanoff, M. Chamberlain, S. Petteway, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1987. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237:888-893.
21. Fouchier, R. A., B. E. Meyer, J. H. Simon, U. Fischer, and M. H. Malim. 1997. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 16:4531-4539.
22. Fouchier, R. A. M., J. H. M. Simon, A. B. Jaffe, and M. H. Malim. 1996. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70:8263-8269.
23. Friedler, A., I. Blumenzweig, L. Baraz, M. Steinitz, M. Kotler, and C. Gilon. 1999. Peptides derived from HIV-1 Vif: a non-substrate-based novel type of HIV-1 protease inhibitors. J. Mol. Biol. 287:93-101.
24. + T lymphocytes. J. Virol. 66:6489-6495.
25. Gallay, P., S. Swingler, C. Aiken, and D. Trono. 1995. HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 80:379-388.
26. Garrett, E. D., L. S. Tiley, and B. R. Cullen. 1991. Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J. Virol. 65:1653-1657.
27. Goncalves, J., Y. Korin, J. Zack, and D. Gabuzda. 1996. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 70:8701-8709.
28. Harmache, A., P. Russo, F. Guiguen, C. Vitu, M. Vignoni, M. Bouyac, C. Hieblot, M. Pepin, R. Vigne, and M. Suzan. 1996. Requirement of caprine arthritis encephalitis virus vifgene for in vivo replication. Virology 224:246-255.
29. Harmache, A., P. Russo, C. Vitu, F. Guiguen, J.-F. Mornex, M. Pepin, R. Vigne, and M. Suzan. 1996. Replication in goats in vivo of caprine arthritisencephalitis virus deleted in vif or tat genes: possible use of these deletion mutants as live vaccines. AIDS Res. Hum. Retrovir. 12:409-411.
30. Hassaine, G., M. Courcoul, G. Bessou, Y. Barthalay, C. Picard, D. Olive, Y. Collette, R. Vigne, and E. Decroly. 2001. The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein. J. Biol. Chem. 276:16885-16893.
31. Henzler, T., A. Harmache, H. Herrmann, H. Spring, M. Suzan, G. Audoly, T. Panek, and V. Bosch. 2001. Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J. Gen. Virol. 82:561-573.
32. Höglund, S., Å. Öhagen, K. Lawrence, and D. Gabuzda. 1994. Role of vif during packing of the core of HIV-1. Virology 201:349-355.
33. Huvent, I., S. S. Hong, C. Fournier, B. Gay, J. Tournier, C. Carrière, M. Courcoul, R. Vigne, B. Spire, and P. Boulanger. 1998. Interaction and coencapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. J. Gen. Virol. 79:1069-1081.
34. Inoshima, Y., M. Kohmoto, Y. Ikeda, H. Yamada, Y. Kawaguchi, K. Tomonaga, T. Miyazawa, C. Kai, T. Umemura, and T. Mikami. 1996. Roles of auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats. J. Virol. 70:8518-8526.
35. Inoshima, Y., T. Miyazawa, and T. Mikami. 1998. The roles of vif and ORF-A genes and AP-1 binding site in in vivo replication of feline immunodeficiency virus. Arch. Virol. 143:789-795.
36. Jacque, J. M., A. Mann, H. Enslen, N. Sharova, B. Brichacek, R. J. Davis, and M. Stevenson. 1998. Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J. 17:2607-2618.
37. Jarmuz, A., A. Chester, J. Bayliss, J. Gisbourne, I. Dunham, J. Scott, and N. Navaratnam. 2002. An anthropoid-specific locus of orphan C to U RNAediting enzymes on chromosome 22. Genomics 79:285-296.
38. Karczewski, M. K., and K. Strebel. 1996. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70:494-507.
39. Khan, M. A., C. Aberham, S. Kao, H. Akari, R. Gorelick, S. Bout Bour, and K. Strebel. 2001. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 75:7252-7265.
40. Kotler, M., M. Simm, Y. S. Zhao, P. Sova, W. Chao, S. F. Ohnona, R. Roller, C. Krachmarov, M. J. Potash, and D. J. Volsky. 1997. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J. Virol. 71:5774-5781.
41. Lee, B., M. Sharron, L. J. Montaner, D. Weissman, and R. W. Doms. 1999. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl. Acad. Sci. USA 96:5215-5220.
42. Liu, H., X. Wu, M. Newman, G. M. Shaw, B. H. Hahn, and J. C. Kappes. 1995. The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J. Virol. 69:7630-7638.
43. Lockridge, K. M., M. Chien, G. A. Dean, K. S. Cole, R. C. Montelaro, P. A. Luciw, and E. E. Sparger. 2000. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 273:67-79.
44. Madani, N., and D. Kabat. 2000. Cellular and viral specificities of human immunodeficiency virus type 1 Vif protein. J. Virol. 74:5982-5987.
45. Madani, N., and D. Kabat. 1998. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72:10251-10255.
46. - mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis. J. Gen. Virol. 79:1945-1950.
47. Ochsenbauer, C., T. Wilk, and V. Bosch. 1997. Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in "nonpermissive" T lymphoid cells stably infected with selectable HIV-1. J. Gen. Virol. 78:627-635.
48. Öhagen, A., and D. Gabuzda. 2000. Role of Vif in stability of the human immunodeficiency virus type 1 core. J. Virol. 74:11055-11066.
49. Ott, D. E., L. V. Coren, D. G. Johnson, B. P. Kane, R. C. Sowder II, Y. D. Kim, R. J. Fisher, X. Z. Zhou, K. P. Lu, and L. E. Henderson. 2000. Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology 266:42-51.
50. Ott, D. E., L. V. Coren, D. G. Johnson, R. C. Sowder II, L. O. Arthur, and L. E. Henderson. 1995. Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain. AIDS Res. Hum. Retrovir. 11:1003-1006.
51. Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792.
52. Potash, M. H., G. Bentsman, T. Muir, C. Krachmarov, P. Sova, and D. J. Volsky. 1998. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc. Natl. Acad. Sci. USA 95:13865-13868.
53. Sakai, H., R. Shibata, J.-I. Sakuragi, S. Sakuragi, M. Kawamura, and A. Adachi. 1993. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67:1663-1666.
54. Seroude, V., G. Audoly, P. Gluschankof, and M. Suzan. 2002. Viral and cellular specificities of caprine arthritis encephalitis virus Vif protein. Virology 292:156-161.
55. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
56. Simm, M., M. Shahabuddin, W. Chao, J. S. Allan, and D. J. Volsky. 1995. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J. Virol. 69:4582-4586.
57. Gag polyprotein of human immunodeficiency virus type I are present in colocalizing membrane-free cytoplasmic complexes. J. Virol. 73:2667-2674.
58. Simon, J. H. M., R. A. M. Fouchier, T. E. Southerling, C. B. Guerra, C. K. Grant, and M. H. Malim. 1997. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J. Virol. 71:5259-5267.
59. Simon, J. H. M., N. C. Gaddis, R. A. M. Fouchier, and M. H. Malim. 1998. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4:1397-1400.
60. Simon, J. H. M., and M. H. Malim. 1996. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70:5297-5305.
61. Simon, J. H. M., D. L. Miller, R. A. M. Fouchier, and M. H. Malim. 1998. Virion incorporation of human immunodeficiency virus type 1 Vif is determined by intracellular expression level and may not be necessary for function. Virology 248:182-187.
62. Simon, J. H. M., D. L. Miller, R. A. M. Fouchier, M. A. Soares, K. W. C. Peden, and M. H. Malim. 1998. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 17:1259-1267.
63. Simon, J. H. M., T. E. Southerling, J. C. Peterson, B. E. Meyer, and M. H. Malim. 1995. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J. Virol. 69:4166-4172.
64. Sova, P., D. Volsky, L. Wang, and W. Chao. 2001. Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed Gag. J. Virol. 75:5504-5517.
65. Sova, P., and D. J. Volsky. 1993. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J. Virol. 67:6322-6326.
66. Tyagi, S., and F. R. Kramer. 1996. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotechnol. 14:303-308.
67. von Schwedler, U., J. Song, C. Aiken, and D. Trono. 1993. vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67:4945-4955.
68. Zhang, H., R. J. Pomerantz, G. Dornadula, and Y. Sun. 2000. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J. Virol. 74:8252-8261.
69. Zimmerman, C., K. C. Klein, P. K. Kiser, A. R. Singh, B. L. Firestein, S. C. Riba, and J. R. Lingappa. 2002. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 415:88-92.